Please assess the completion status of the following clinical trial:

Trial Title: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized~* Must be first admission of COVID-19, not re-admission~* Primary reason for hospitalization or prolonged hospitalization is because of acute COVID-19 diagnosis~* Adults 18 years of age or greater~* Laboratory-proven COVID-19 within 14 days prior to hospital admission~Exclusion Criteria:~* Hypotension (SAP \< 100 mmHg or DAP \< 50 mmHg or MAP \< 65 mmHg)~* Hyperkalemia (\> 5.5 mmol/l)~* Acute kidney injury (urine output \< 0.5 ml/kg/hr and new creatinine \> 200 mmol/l, or increase \> 100 mmol/l, or GFR \< 30 ml/min)~* Use of aliskiren in patients with diabetes mellitus (type 1 or type 2) or moderate-severe renal impairment (GFR less than 60mL/min)~* Use of ARB/ACEi within 7 days of presentation~* Pregnant or breastfeeding~* Have a known allergy to ARBs or any component of the drug product~* Have written legal document to withhold life-sustaining (patients not wishing to receive Cardiopulmonary Resuscitation (CPR) can participate if other medical treatments will be given)~* Have signed a Do No Resuscitate (DNR) Form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan) (Type: EXPERIMENTAL): Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at initial or higher dose.
- Usual Care Control (Type: NO_INTERVENTION): Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country

Based on this trial design, predict the completion outcome and termination type (if applicable).